According to an official statement released by the Council of Scientific and Industrial Research (CSIR), the Mumbai based Pharmaceutical company Cipla is ready to launch its COVID-19 treatment drug Favipiravir.
The drug has been developed CSIR. To make the drug cost-effective, the CSIR-Indian Institute of Chemical Technology (CSIR-IICT) developed a process of using locally available chemicals to synthesize the Active Pharmaceutical Ingredient (API) and transferred the technology to Cipla.